MAP
NKTR icon

Moody Aldrich Partners’s Nektar Therapeutics NKTR Stock Holding History

Moody Aldrich Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.48M Sell
64,135
-25,392
-28% -$1.86M 0.8% 55
2026
Q1 		$6.44M Buy
89,527
+33,504
+60% +$1.91M 1.16% 18
2025
Q4 		$2.37M Sell
56,023
-17,693
-24% -$990K 0.44% 100
2025
Q3 		$4.19M Buy
73,716
+28,304
+62% +$937K 0.8% 57
2025
Q2 		$1.17M Buy
+45,412
New +$510K 0.23% 110

Other funds holding NKTR

G
Gainplan Bloomfield Hills, Michigan $254M AUM 25.62% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return

Moody Aldrich Partners's NKTR Position: Q2 2026 in Review

Moody Aldrich Partners reduced its Nektar Therapeutics (NKTR) stake by 28% in Q2 2026, selling an estimated $1.86M and leaving 64,135 shares worth $4.48M. The position accounts for 0.8% of the portfolio, ranked #55.

Moody Aldrich Partners first reported a position in NKTR in Q2 2025 and has held it in 5 quarters since. The position peaked at $6.44M in Q1 2026. 11 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Moody Aldrich Partners held 64,135 shares of Nektar Therapeutics worth $4.48M as of Q2 2026.
  • Moody Aldrich Partners sold 25,392 Nektar Therapeutics shares in Q2 2026, an estimated $1.86M.
  • Nektar Therapeutics made up 0.8% of Moody Aldrich Partners's portfolio in Q2 2026, its #55 holding.
  • Moody Aldrich Partners first reported a position in Nektar Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Moody Aldrich Partners's Nektar Therapeutics position peaked at $6.44M in Q1 2026.
  • 11 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Moody Aldrich Partners's 13F filing for Q2 2026, filed 15 Jul 2026.